NCT00850122View on ClinicalTrials.gov

An Open Label Study to Describe the Pharmacokinetics of Cefazolin in Preterm Neonates

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

July 31, 2018

Study Completion Date

July 31, 2018

Conditions
SepsisPrematurity
Interventions
DRUG

cefazolin

"Cefazolin dosing - administered for 48 hours Dosage~≤28 days of age 25 mg/kg IV q12 29-120 days of age 25 mg/kg IV q8"

Trial Locations (1)

Unknown

Federal University of Sao Paulo, São Paulo

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Phillip Brian Smith

OTHER

NCT00850122 - An Open Label Study to Describe the Pharmacokinetics of Cefazolin in Preterm Neonates | Biotech Hunter | Biotech Hunter